Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

NCT03954132 · clinicaltrials.gov ↗

COMPLETED

Status

469

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Spiolto® Respimat®
DRUG: Triple-Therapy (LAMA/LABA/ICS)

Sponsor

Boehringer Ingelheim